HR 4 Under Consideration by US House

The House will consider HR 4 by the end of this week as part of their 100 hour agenda. HR 4 would significantly change the Medicare Part D benefit by allowing the federal government to directly negotiate drug prices. Our national organization has put together a well-developed letter that outlines specific concerns with HR 4 (see the 1/10 issue of Mid Week Minute to access the letter). The cost of pharmaceuticals is a topic meritorious of debate; however, it is important to note that it is a complex issue and for every decision there are unanticipated consequences. Policy makers should remember that the people who rely upon these life-saving medications cannot become pawns in this game of economic chess. People experiencing chronic health conditions, whether they be related to mental illness or cancer, deserve access to therapies that work. As always, we welcome your thoughts!